Bengaluru: Novo Nordisk, a global healthcare company and leader in diabetes and haemophilia care, marked World Haemophilia Day by organising awareness camps in 56 cities, with the support of the Haemophilia Federation of India state chapters.
Themed ‘Hear Their Voices’, these camps were attended by over 7,000 people along with their caregivers and families. These educational workshops were instrumental in creating more awareness about haemophilia management and treatment.
Underlining the need to generate more awareness about this rare hereditary disorder and the role played by Indian women in managing family member with haemophilia, Melvin D’souza, Corporate Vice President and General Manager, Novo Nordisk India said: “India has the highest number of people with haemophilia A globally. There are reported 14,508 people with haemophilia A. There is a growing need to ensure that every person with haemophilia is made aware of the symptoms and treatment available. And for this, we need to reach out to the women in the family who are the primary caregivers to people with haemophilia. We are thankful to the Haemophilia Federation of India for their support in making India a more aware nation about haemophilia.”
Mr Vikash Goel, President, Haemophilia Federation of India commenting on the awareness camps said: “The majority of people with haemophilia in India are less than 18 years of age or in the reproductive age group. This initiative has helped connect with over 7000 people. Enhanced awareness about haemophilia ensures that person with haemophilia is detected early and initiation of right treatment is done early to minimise related risks.”
Haemophilia is a hereditary disorder of blood coagulation due to decreased levels or a complete lack of clotting factors and results in profuse bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma. The number of bleeding episodes may vary depending on the severity of the condition that is based on the level of residual clotting factors present in blood. By regular replacement therapy with clotting factors, the number of bleeding episodes are reduced to maximum possible extent.